FLGT on XNAS, Health Care, Fulgent Genetics, Inc., job postings
Measures activity, not value. Not investment advice.
Shares up 20% in a month but down 16% in a year, while the 12-month net loss hit $90.9M.
GoodLatest quarter revenue rose 7.5% to $90.4M from a year earlier
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
expected around 26 Feb 2027 (an estimate: a year ago it reported on 27 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $90.4M, net loss $13.2M.
31 Dec 2021RevenueNet incomeNet losstallest bar $320.4M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$90.4M
-$13.2M
30 Jun 2026
$85.4M
-$29.5M
31 Mar 2026
$71.1M
-$24.8M
31 Dec 2025
$83.3M
-$23.4M
30 Sep 2025
$84.1M
-$6.6M
30 Jun 2025
$81.8M
-$19.0M
31 Mar 2025
$73.5M
-$11.5M
31 Dec 2024
$76.2M
-$5.9M
30 Sep 2024
$71.7M
-$14.6M
30 Jun 2024
$71.0M
-$8.7M
31 Mar 2024
$64.5M
-$13.5M
31 Dec 2023
$70.5M
-$128.1M
30 Sep 2023
$84.7M
-$13.1M
30 Jun 2023
$67.9M
-$11.2M
31 Mar 2023
$66.2M
-$15.3M
31 Dec 2022
$67.7M
-$23.8M
30 Sep 2022
$105.7M
$1.7M
30 Jun 2022
$125.4M
$11.5M
31 Mar 2022
$320.4M
$154.0M
31 Dec 2021
$251.7M
$104.3M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$330.3M
$315.5M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+4.7%
+17%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$90.9M
-$43.0M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
33.8%
41.2%
33.5%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-39.2%
-22.5%
-8.2%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-27.5%
-13.6%
-5.9%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-8.6%
-10.1%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$1.4M
-$19.8M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$292.7M
$117.6M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$2.0M
$2.4M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$290.8M (net cash)
-$115.2M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.00
0.16
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$35.45
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
29.1
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
2.0
3.6
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
1.2
2.6
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.68
2.8
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+7.5%
$90.4M vs $84.1M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
-70%
$1.8M vs $6.0M (quarter ended 30 Sep 2026)
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$117K
bought $0, sold $117K
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+1.4%
140 13F filers vs 138
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
54%
15.2M shares held by 13F filers (30 Sep 2026) of 27.9M outstanding (2 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
7.2%
2.0M shares sold short (30 Oct 2026) of 27.9M outstanding (2 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
7.8
2.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-5.4%
2.1M shares sold short in the report before, 2.0M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
49%
49% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 50%
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$5.0M
the 12 months before: $5.3M
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
17
17 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
17 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.
Price $24.12 on 20 Nov 2026, -16% over 12 months (12-month range $13.79 to $30.85)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $350K in the last 12 months (the 12 months before: $994K).Revenue per quarter. Revenue $90.4M in the latest quarter, +7.5% on a year earlier.Capital spending per quarter. Capital spending $1.8M in the latest quarter, -70% on a year earlier.Institutional holders (13F filers). 140 13F filers reported holding it in the latest 13F quarter, -8.5% on a year earlier.Federal obligations. Federal obligations: $219K published in the last 12 months, -96% on the 12 months before.Lobbying spend. Lobbying spend: $0 published in the last 12 months, -100% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $251.7M, -15% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $320.4M, -11% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $125.4M, -18% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $105.7M, -54% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $67.7M, -73% on a year earlier; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $66.2M, -79% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $67.9M, -46% on a year earlier; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $84.7M, -20% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Dec 2023: $70.5M, +4.2% on a year earlier; public on 29 Feb 2024
Quarter ended 31 Mar 2024: $64.5M, -2.6% on a year earlier; public on 4 May 2024
Quarter ended 30 Jun 2024: $71.0M, +4.6% on a year earlier; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $71.7M, -15% on a year earlier; public on 9 Nov 2024
Quarter ended 31 Dec 2024: $76.2M, +8.0% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $73.5M, +14% on a year earlier; public on 3 May 2025
Quarter ended 30 Jun 2025: $81.8M, +15% on a year earlier; public on 2 Aug 2025
Quarter ended 30 Sep 2025: $84.1M, +17% on a year earlier; public on 8 Nov 2025
Quarter ended 31 Dec 2025: $83.3M, +9.3% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $71.1M, -3.2% on a year earlier; public on 2 May 2026
Quarter ended 30 Jun 2026: $85.4M, +4.4% on a year earlier; public on 31 Jul 2026
Quarter ended 30 Sep 2026: $90.4M, +7.5% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $6.0M, -75% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $5.4M, -53% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $3.3M, +11% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $5.4M, +60% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $4.7M, -21% on a year earlier; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $2.0M, -62% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $12.1M, +273% on a year earlier; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $4.9M, -9.4% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Dec 2023: $3.1M, -34% on a year earlier; public on 29 Feb 2024
Quarter ended 31 Mar 2024: $4.1M, +99% on a year earlier; public on 4 May 2024
Quarter ended 30 Jun 2024: $12.9M, +6.6% on a year earlier; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $19.5M, +297% on a year earlier; public on 9 Nov 2024
Quarter ended 31 Dec 2024: $3.8M, +22% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $4.7M, +16% on a year earlier; public on 3 May 2025
Quarter ended 30 Jun 2025: $6.8M, -47% on a year earlier; public on 2 Aug 2025
Quarter ended 30 Sep 2025: $6.0M, -69% on a year earlier; public on 8 Nov 2025
Quarter ended 31 Dec 2025: $5.0M, +32% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $5.2M, +10% on a year earlier; public on 2 May 2026
Quarter ended 30 Jun 2026: $3.9M, -43% on a year earlier; public on 31 Jul 2026
Quarter ended 30 Sep 2026: $1.8M, -70% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 265; public on 14 Feb 2022
31 Mar 2022 report: 249; public on 16 May 2022
30 Jun 2022 report: 241; public on 15 Aug 2022
30 Sep 2022 report: 213; public on 14 Nov 2022
31 Dec 2022 report: 200; public on 14 Feb 2023
31 Mar 2023 report: 198; public on 15 May 2023
30 Jun 2023 report: 192; public on 14 Aug 2023
30 Sep 2023 report: 179; public on 14 Nov 2023
31 Dec 2023 report: 181; public on 14 Feb 2024
31 Mar 2024 report: 168; public on 15 May 2024
30 Jun 2024 report: 164; public on 14 Aug 2024
30 Sep 2024 report: 174; public on 14 Nov 2024
31 Dec 2024 report: 184; public on 14 Feb 2025
31 Mar 2025 report: 166; public on 15 May 2025
30 Jun 2025 report: 161; public on 14 Aug 2025
30 Sep 2025 report: 153; public on 14 Nov 2025
31 Dec 2025 report: 173; public on 17 Feb 2026
31 Mar 2026 report: 152; public on 15 May 2026
30 Jun 2026 report: 138; public on 14 Aug 2026
30 Sep 2026 report: 140; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $11.4M published
Month from 1 Jan 2022: -$77K published
Month from 1 Mar 2022: -$6.6M published
Month from 1 May 2022: -$160K published
Month from 1 Jun 2022: -$56K published
Month from 1 Aug 2022: $24K published
Month from 1 Sep 2022: $24K published
Month from 1 Oct 2022: $2.2M published
Month from 1 Nov 2022: $0 published
Month from 1 Dec 2022: -$35K published
Month from 1 Jan 2023: -$52K published
Month from 1 Feb 2023: $202K published
Month from 1 Jul 2023: $0 published
Month from 1 Sep 2023: $2.0M published
Month from 1 Oct 2023: $163K published
Month from 1 Nov 2023: $30K published
Month from 1 Mar 2024: $0 published
Month from 1 Apr 2024: $25K published
Month from 1 May 2024: $87K published
Month from 1 Aug 2024: $49K published
Month from 1 Sep 2024: $2.2M published
Month from 1 Oct 2024: $2.5M published
Month from 1 Nov 2024: $0 published
Month from 1 Dec 2024: -$3K published
Month from 1 Jan 2025: $0 published
Month from 1 Mar 2025: -$24K published
Month from 1 Apr 2025: $0 published
Month from 1 Jun 2025: -$47K published
Month from 1 Jul 2025: $598K published
Month from 1 Aug 2025: $0 published
Month from 1 Sep 2025: $6.7M published
Month from 1 Oct 2025: $200K published
Month from 1 Nov 2025: -$1.9M published
Month from 1 Dec 2025: -$6K published
Month from 1 Feb 2026: -$14K published
Month from 1 Apr 2026: $0 published
Month from 1 May 2026: $0 published
Month from 1 Jun 2026: $49K published
Month from 1 Aug 2026: $0 published
Month from 1 Sep 2026: $7K published
Month from 1 Oct 2026: $184K published
Lobbying spend
Quarter from 1 Oct 2022: $120K published
Quarter from 1 Jan 2023: $50K published
Quarter from 1 Apr 2024: $60K published
Quarter from 1 Apr 2025: $20K published
Quarter from 1 Jul 2025: $30K published
Quarter from 1 Oct 2025: $30K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is capital expenditure, quarter at $1.8M (30 Sep 2026), 65% below its normal quarter of $5.1M; higher than 39% of its own history.
In 12 months: 3 major agreements, 1 completed deal, 1 director or officer change. Results releases and routine reports are left out.
Filed
What happened
Source
18 Nov 2026
Entered lease with EP 63 Kendrick Realty LLC for about 44,644 sq ft in Needham, Massachusetts; 126-month term, $132,071.83 monthly initial rentSame filing: took on new debt
Reported lobbying spend: $30K in Q3 2025, $30K in Q2 2025. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
1 Jul 2025
Ended
Washington Strategic Consultingfor Mintz Levin (On Behalf Of Fulgent Genetics, Inc.)
Uninsured Program Fund (Pub. L. 116-136, Pub. L. 116-260)Health issues
Two or more unrelated kinds of records unusual within 30 days
17 Aug 2021confirmed
Confirmed across sources Government contracts and Filings + Financials
Fulgent Genetics(FLGT): booked $11.7M in federal contract and grant obligations in July 2021, against none in the same month last year, while it reported revenue of $153.6M for the quarter ended 30 Jun 2021, 8.9× the same quarter last year. Two unrelated kinds of activity within 7 days.
Government contracts: Federal obligations jump, became public on 19 Jul 2021
Financials: Quarterly revenue change, became public on 17 Aug 2021
July 2021 against the 3 months before it.
this monthearliernormal: $0See the evidence (2 changes)
Government contracts: Federal obligations jump became public on 19 Jul 2021
Fulgent Genetics booked $11.7M in federal contract and grant obligations in July 2021, against none in the same month last year.
This period
$11.7M (July 2021)
Normal month (median of 3 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+11.7
Same month last year
$0
History used
1,405 days
July 20213 earlier monthsnormal: $0
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Financials: Quarterly revenue change became public on 17 Aug 2021
Fulgent Genetics reported revenue of $153.6M for the quarter ended 30 Jun 2021, 8.9× the same quarter last year.
This period
$153.6M (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
$13.8M
Typical spread (median absolute deviation)
$5.7M
How far from its usual level
+16.4
Same quarter last year
$17.3M
History used
2,283 days
the quarter ended 30 Jun 20218 earlier quartersnormal: $13.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
13 Oct 2020confirmed
Confirmed across sources Government contracts and Filings + Financials and Short interest and volume
Fulgent Genetics(FLGT): had 3.7M shares sold short in the 30 Nov 2020 report, 20× the same report last year; it also reported revenue of $295.0M for the quarter ended 31 Dec 2020, 35× the same quarter last year; and it booked $24.1M in federal contract and grant obligations in March 2021, against none in the same month last year. Three unrelated kinds of activity within 195 days.
Government contracts: First award from a new federal agency, became public on 23 Sep 2020
Short interest and volume: Short interest spike, became public on 10 Oct 2020
Financials: Quarterly capital spending jump, became public on 10 Nov 2020
Financials: Quarterly revenue change, became public on 10 Nov 2020
Short interest and volume: Short interest spike, became public on 25 Nov 2020
Short interest and volume: Short interest spike, became public on 10 Dec 2020
Short interest and volume: Short interest spike, became public on 25 Dec 2020
Short interest and volume: Short interest spike, became public on 13 Jan 2021
Short interest and volume: Short interest spike, became public on 28 Jan 2021
Short interest and volume: Short interest spike, became public on 10 Feb 2021
Financials: Quarterly capital spending jump, became public on 9 Mar 2021
Financials: Quarterly revenue change, became public on 9 Mar 2021
Government contracts: First award from a new federal agency, became public on 17 Mar 2021
Government contracts: Federal obligations jump, became public on 23 Mar 2021
The 30 Nov 2020 report against the 24 reports before it.
this reportearliernormal: 763KSee the evidence (14 changes)
Government contracts: First award from a new federal agency became public on 23 Sep 2020
Fulgent Genetics won its first award from the Department of Homeland Security, a $1.4M contract, after 1 earlier federal award from other agencies.
"First" means first in our data: it fires only when the source's history began at least 365 days earlier.
Short interest and volume: Short interest spike became public on 10 Oct 2020
Fulgent Genetics had 1.9M shares sold short in the 30 Sep 2020 report, 21× the same report last year.
This period
1.9M (the 30 Sep 2020 report)
Normal report (median of 24 earlier)
487K
Typical spread (median absolute deviation)
276K
How far from its usual level
+3.5
Same report last year
93K
History used
1,006 days
the 30 Sep 2020 report24 earlier reportsnormal: 487K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly capital spending jump became public on 10 Nov 2020
Fulgent Genetics spent $10.1M on capital projects in the quarter ended 30 Sep 2020, 115× the same quarter last year.
This period
$10.1M (the quarter ended 30 Sep 2020)
Normal quarter (median of 8 earlier)
$480K
Typical spread (median absolute deviation)
$352K
How far from its usual level
+9.6
Same quarter last year
$88K
History used
1,735 days
the quarter ended 30 Sep 20208 earlier quartersnormal: $480K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Financials: Quarterly revenue change became public on 10 Nov 2020
Fulgent Genetics reported revenue of $101.7M for the quarter ended 30 Sep 2020, 9.8× the same quarter last year.
This period
$101.7M (the quarter ended 30 Sep 2020)
Normal quarter (median of 8 earlier)
$8.1M
Typical spread (median absolute deviation)
$2.3M
How far from its usual level
+27.0
Same quarter last year
$10.3M
History used
2,010 days
the quarter ended 30 Sep 20208 earlier quartersnormal: $8.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 25 Nov 2020
Fulgent Genetics had 3.0M shares sold short in the 13 Nov 2020 report, 13× the same report last year.
This period
3.0M (the 13 Nov 2020 report)
Normal report (median of 24 earlier)
726K
Typical spread (median absolute deviation)
361K
How far from its usual level
+4.3
Same report last year
229K
History used
1,050 days
the 13 Nov 2020 report24 earlier reportsnormal: 726K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Dec 2020
Fulgent Genetics had 3.7M shares sold short in the 30 Nov 2020 report, 20× the same report last year.
This period
3.7M (the 30 Nov 2020 report)
Normal report (median of 24 earlier)
763K
Typical spread (median absolute deviation)
397K
How far from its usual level
+4.9
Same report last year
183K
History used
1,067 days
the 30 Nov 2020 report24 earlier reportsnormal: 763K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Dec 2020
Fulgent Genetics had 3.2M shares sold short in the 15 Dec 2020 report, 15× the same report last year.
This period
3.2M (the 15 Dec 2020 report)
Normal report (median of 24 earlier)
766K
Typical spread (median absolute deviation)
401K
How far from its usual level
+4.1
Same report last year
217K
History used
1,082 days
the 15 Dec 2020 report24 earlier reportsnormal: 766K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Jan 2021
Fulgent Genetics had 3.9M shares sold short in the 31 Dec 2020 report, 14× the same report last year.
This period
3.9M (the 31 Dec 2020 report)
Normal report (median of 24 earlier)
848K
Typical spread (median absolute deviation)
440K
How far from its usual level
+4.7
Same report last year
290K
History used
1,098 days
the 31 Dec 2020 report24 earlier reportsnormal: 848K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 Jan 2021
Fulgent Genetics had 4.1M shares sold short in the 15 Jan 2021 report, 14× the same report last year.
This period
4.1M (the 15 Jan 2021 report)
Normal report (median of 24 earlier)
929K
Typical spread (median absolute deviation)
521K
How far from its usual level
+4.2
Same report last year
290K
History used
1,113 days
the 15 Jan 2021 report24 earlier reportsnormal: 929K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Feb 2021
Fulgent Genetics had 4.2M shares sold short in the 29 Jan 2021 report, 17× the same report last year.
This period
4.2M (the 29 Jan 2021 report)
Normal report (median of 24 earlier)
938K
Typical spread (median absolute deviation)
530K
How far from its usual level
+4.1
Same report last year
250K
History used
1,127 days
the 29 Jan 2021 report24 earlier reportsnormal: 938K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly capital spending jump became public on 9 Mar 2021
Fulgent Genetics spent $23.8M on capital projects in the quarter ended 31 Dec 2020, 52× the same quarter last year.
This period
$23.8M (the quarter ended 31 Dec 2020)
Normal quarter (median of 8 earlier)
$480K
Typical spread (median absolute deviation)
$352K
How far from its usual level
+23.3
Same quarter last year
$461K
History used
1,827 days
the quarter ended 31 Dec 20208 earlier quartersnormal: $480K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Financials: Quarterly revenue change became public on 9 Mar 2021
Fulgent Genetics reported revenue of $295.0M for the quarter ended 31 Dec 2020, 35× the same quarter last year.
This period
$295.0M (the quarter ended 31 Dec 2020)
Normal quarter (median of 8 earlier)
$8.4M
Typical spread (median absolute deviation)
$2.3M
How far from its usual level
+82.7
Same quarter last year
$8.4M
History used
2,102 days
the quarter ended 31 Dec 20208 earlier quartersnormal: $8.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Government contracts: First award from a new federal agency became public on 17 Mar 2021
Fulgent Genetics won its first award from the Department of Health and Human Services, a $24.1M contract, after 2 earlier federal awards from other agencies.
"First" means first in our data: it fires only when the source's history began at least 365 days earlier.
Government contracts: Federal obligations jump became public on 23 Mar 2021
Fulgent Genetics booked $24.1M in federal contract and grant obligations in March 2021, against none in the same month last year.
This period
$24.1M (March 2021)
Normal month (median of 3 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+24.1
Same month last year
$0
History used
1,283 days
March 20213 earlier monthsnormal: $0
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
19 May 2020confirmed
Confirmed across sources Government contracts and Institutional holdings and Short interest and volume
Fulgent Genetics(FLGT): had 769K shares sold short in the 30 Apr 2020 report, 66× the same report last year; it also saw 20 13F filers open a new position in the quarter ended 31 Mar 2020, 10× the same quarter last year; and it won its first federal award in our data, a $3.1M Department of Veterans Affairs contract. Three unrelated kinds of activity within 33 days.
Short interest and volume: Short interest spike, became public on 12 May 2020
Institutional holdings: Many funds opening a new position, became public on 15 May 2020
Government contracts: First federal award, became public on 15 Jun 2020
The 30 Apr 2020 report against the 24 reports before it.
this reportearliernormal: 122KSee the evidence (3 changes)
Short interest and volume: Short interest spike became public on 12 May 2020
Fulgent Genetics had 769K shares sold short in the 30 Apr 2020 report, 66× the same report last year.
This period
769K (the 30 Apr 2020 report)
Normal report (median of 24 earlier)
122K
Typical spread (median absolute deviation)
115K
How far from its usual level
+3.8
Same report last year
12K
History used
853 days
the 30 Apr 2020 report24 earlier reportsnormal: 122K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 May 2020
Fulgent Genetics saw 20 13F filers open a new position in the quarter ended 31 Mar 2020, 10× the same quarter last year.
This period
20 (the quarter ended 31 Mar 2020)
Normal quarter (median of 8 earlier)
2
Typical spread (median absolute deviation)
2
How far from its usual level
+6.0
Same quarter last year
2
History used
1,278 days
the quarter ended 31 Mar 20208 earlier quartersnormal: 2
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
"First" means first in our data: it fires only when the source's history began at least 365 days earlier.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
14 May 2026Filings change
filed a director or officer change (8-K item 5.02), its first in 90 days.
Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.
had 2.7M shares sold short in the 15 Apr 2026 report, 1.5× the same report last year.
Same report last year: 1.8M; its normal report is 1.8M.
See the evidence
This period
2.7M (the 15 Apr 2026 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
150K
How far from its usual level
+3.7
Same report last year
1.8M
History used
3,029 days
the 15 Apr 2026 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
booked $6.7M in federal contract and grant obligations in September 2025, 1.5× the same month last year.
Same month last year: $4.5M; its normal month is $2.0M.
See the evidence
This period
$6.7M (September 2025)
Normal month (median of 5 earlier)
$2.0M
Typical spread (median absolute deviation)
$582K
How far from its usual level
+4.7
Same month last year
$4.5M
History used
2,927 days
September 20255 earlier monthsnormal: $2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
had 1.6M shares sold short in the 30 May 2025 report, 2.2× the same report last year.
Same report last year: 721K; its normal report is 784K.
See the evidence
This period
1.6M (the 30 May 2025 report)
Normal report (median of 24 earlier)
784K
Typical spread (median absolute deviation)
141K
How far from its usual level
+3.9
Same report last year
721K
History used
2,709 days
the 30 May 2025 report24 earlier reportsnormal: 784K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.8M shares sold short in the 15 May 2025 report, 2.5× the same report last year.
Same report last year: 704K; its normal report is 783K.
See the evidence
This period
1.8M (the 15 May 2025 report)
Normal report (median of 24 earlier)
783K
Typical spread (median absolute deviation)
122K
How far from its usual level
+5.5
Same report last year
704K
History used
2,694 days
the 15 May 2025 report24 earlier reportsnormal: 783K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.7M shares sold short in the 30 Apr 2025 report, 2.5× the same report last year.
Same report last year: 682K; its normal report is 766K.
See the evidence
This period
1.7M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
766K
Typical spread (median absolute deviation)
86K
How far from its usual level
+7.6
Same report last year
682K
History used
2,679 days
the 30 Apr 2025 report24 earlier reportsnormal: 766K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.8M shares sold short in the 15 Apr 2025 report, 2.8× the same report last year.
Same report last year: 625K; its normal report is 741K.
See the evidence
This period
1.8M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
741K
Typical spread (median absolute deviation)
73K
How far from its usual level
+9.5
Same report last year
625K
History used
2,664 days
the 15 Apr 2025 report24 earlier reportsnormal: 741K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.5M shares sold short in the 31 Mar 2025 report, 2.5× the same report last year.
Same report last year: 604K; its normal report is 728K.
See the evidence
This period
1.5M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
728K
Typical spread (median absolute deviation)
69K
How far from its usual level
+7.7
Same report last year
604K
History used
2,649 days
the 31 Mar 2025 report24 earlier reportsnormal: 728K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.6M shares sold short in the 14 Mar 2025 report, 2.7× the same report last year.
Same report last year: 611K; its normal report is 722K.
See the evidence
This period
1.6M (the 14 Mar 2025 report)
Normal report (median of 24 earlier)
722K
Typical spread (median absolute deviation)
69K
How far from its usual level
+9.0
Same report last year
611K
History used
2,632 days
the 14 Mar 2025 report24 earlier reportsnormal: 722K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.4M shares sold short in the 28 Feb 2025 report, 2.8× the same report last year.
Same report last year: 498K; its normal report is 712K.
See the evidence
This period
1.4M (the 28 Feb 2025 report)
Normal report (median of 24 earlier)
712K
Typical spread (median absolute deviation)
71K
How far from its usual level
+6.3
Same report last year
498K
History used
2,618 days
the 28 Feb 2025 report24 earlier reportsnormal: 712K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.3M shares sold short in the 14 Feb 2025 report, 2.5× the same report last year.
Same report last year: 517K; its normal report is 702K.
See the evidence
This period
1.3M (the 14 Feb 2025 report)
Normal report (median of 24 earlier)
702K
Typical spread (median absolute deviation)
78K
How far from its usual level
+5.1
Same report last year
517K
History used
2,604 days
the 14 Feb 2025 report24 earlier reportsnormal: 702K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.1M shares sold short in the 15 Jan 2025 report, 2.1× the same report last year.
Same report last year: 508K; its normal report is 688K.
See the evidence
This period
1.1M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
688K
Typical spread (median absolute deviation)
70K
How far from its usual level
+3.7
Same report last year
508K
History used
2,574 days
the 15 Jan 2025 report24 earlier reportsnormal: 688K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
spent $19.5M on capital projects in the quarter ended 30 Sep 2024, 4.0× the same quarter last year.
Same quarter last year: $4.9M; its normal quarter is $4.8M.
See the evidence
This period
$19.5M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$4.8M
Typical spread (median absolute deviation)
$1.2M
How far from its usual level
+8.0
Same quarter last year
$4.9M
History used
3,196 days
the quarter ended 30 Sep 20248 earlier quartersnormal: $4.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
spent $12.1M on capital projects in the quarter ended 30 Jun 2023, 3.7× the same quarter last year.
Same quarter last year: $3.3M; its normal quarter is $4.1M.
See the evidence
This period
$12.1M (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
$4.1M
Typical spread (median absolute deviation)
$1.2M
How far from its usual level
+4.5
Same quarter last year
$3.3M
History used
2,738 days
the quarter ended 30 Jun 20238 earlier quartersnormal: $4.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
booked $11.4M in federal contract and grant obligations in December 2021, against a normal month of $0.
Same month a year earlier: -$168K.
See the evidence
This period
$11.4M (December 2021)
Normal month (median of 4 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+11.4
Same month last year
-$168K
History used
1,558 days
December 20214 earlier monthsnormal: $0
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Showing the newest 40 of 92 entries; narrow the window or the kind of data to see older ones.
Not listed: 232 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001674930
Ticker
FLGT
Domain
fulgentgenetics.com
Employer name
Fulgent Therapeutics, LLC (1 unverified)
Fein
32-0400050 (1 unverified)
Hq location
CA|EL MONTE|91731 (1 unverified)
Lobbying client
mintz levin on behalf of fulgent genetics, mintz on behalf of fulgent genetics
Name
ANP Technologies, Inc, Cytometry Specialists, Inc, Fulgent Australia Pty Ltd, Fulgent Diagnostics, Inc. and 5 more
Uei
Y9JMAEN8GRK6
Wikidata
Q66823616
DOL H-1B labor condition applications and PERM certifications2 data points24 Nov 2025 to 24 Nov 2025
Federal lobbying disclosures (LDA)6 records, 34 data points28 Jul 2022 to 31 Mar 2026
SEC Form 13F institutional holdings369 data points30 Sep 2016 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)122 records2 Sep 2016 to 18 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)776 data points31 Dec 2013 to 2 Nov 2026
SEC Form 4 insider transactions141 records, 352 data points4 Oct 2016 to 3 Sep 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4152 data points2 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards6 records, 228 data points25 Sep 2017 to 6 Oct 2026